Nanomerics has entered into an Engineering and Physical Sciences Research Council (EPSRC) funded academic collaboration with scientists from Exeter University, Cambridge University, University College London and The Science and Technology Facilities Council’s Central Laser Facility. The £5.7 million pound grant will generate new data on the diagnosis and treatment of solid tumours with gold nanoparticles. The Raman Nanotheranostics (RaNT) grant will utilise Nanomerics’ Molecular Envelope Technology (MET) to synthesis targeted diagnostics that combine light and functionalised particles. The research team behind the project believe it has the potential not just to increase survival rates and quality of life, but also potentially save many hundreds of millions of pounds across the UK each year by reducing numbers of ineffective or unnecessary treatments. The project aims to use the emerging field of nanotheranostics – a combination of therapy and diagnosis to identify and treat disease in a single, effective non-surgical procedure. The research team will use gold nanotechnologies – small, non-toxic gold particles which can be used both for identifying and localising disease as well as for targeted treatments using light to destroy diseased cells in the body in a controlled and safe manner. The research will also aim to provide more accurate diagnosis by pinpointing specific cells, and also lead to improved localised treatment that can be tailored to each individual patient.
The substantial grant was allocated as part of the EPSRC’s Programmes in Healthcare Technologies scheme.
Professor Andreas G. Schatzlein, CEO of Nanomerics says, "Nanomerics are really fortunate to be part of such a high powered research team, engaging in really important research, with the potential to stop metastatic cancers from claiming millions of lives every year.”